Answer：United Imaging Healthcare was founded in 2011 in Shanghai, China. The company's headquarters are in Shanghai, with regional headquarters and R&D centers in the United States, Singapore, Netherland, France, and Japan, and the UAE. The company also has manufacturing facilities in Shanghai, Changzhou, Wuhan, and Houston (USA), supported by a global sales and service network. As of the end of the reporting period, the company had deployed over 37,300 systems in more than 15,700 medical and research institutions worldwide, including over 1,000 top-tier hospitals in China. The company's business had expanded to over 90 countries and regions across Asia, the Americas, Europe, Oceania, and Africa

Answer：United Imaging Healthcare provides high-end medical imaging diagnostic equipment, radiation therapy products, life science instruments, and medical digital and intelligent solutions. Its product lineup includes magnetic resonance imaging systems (MR), X-ray computed tomography systems (CT), X-ray imaging systems (XR), molecular imaging systems (PET/CT and PET/MR), medical linear accelerators (RT), and life science instruments. In digital diagnosis and treatment, the company offers cloud-based solutions that integrate equipment and applications, enabling medical resource sharing and comprehensive services for end-users.

Answer：United Imaging Healthcare has embraced globalization as a core strategy to realize its vision of becoming a world-class leader in medical innovation. The company's international progress over the past few years reflects this strategic focus, especially in high-end hospitals and research institutions. In the first three quarters of 2024, the company saw overseas revenue reach 1.404 billion CNY, a 36.49% year-on-year increase, with service revenue growing by over 100%, and overseas revenue now accounting for more than 20% of the total.
United Imaging's products currently serve over 13,000 medical and research institutions across more than 75 countries and regions. In the U.S., the company is accelerating the market adoption of high-end innovative products. Its advanced systems have been successfully installed at leading clinical and research centers such as Washington University School of Medicine, UC Davis, UC San Diego, Michigan State University Innovation Center, McGovern Medical School at the University of Texas, Carrollton Regional Medical Center (CRMC), Stony Brook University, and the Huntsman Cancer Institute at the University of Utah. These partnerships underscore United Imaging's growing traction in the U.S. market.
In Europe, the company has successfully deployed its full imaging product line, with installations at renowned institutions like Bologna University Hospital in Italy and the Maria Skłodowska-Curie National Research Institute of Oncology in Poland. Additionally, in 2024, the company introduced digital PET/CT technology to the French market, marking a milestone in the region.United Imaging's global brand and academic presence are also expanding. At the SNMMI 2023, the debut of NeuroEXPLORER (NX), the world's first digital brain-dedicated PET/CT system, was celebrated as a highlight in neuroscience. The system later won the 2024 SNMMI "Image of the Year" award, further enhancing the company's visibility in the medical imaging community.
The global medical imaging and radiotherapy equipment market is projected to surpass $60 billion in 2024, with forecasts reaching $75 billion by 2030, according to CIC Consulting. The Chinese market is expected to contribute about 20% of this total, while international markets will account for the remaining 80%. The growth is driven by factors such as an aging global population, an increase in chronic diseases, and rising healthcare spending. Additionally, the demand for equipment replacement in developed markets and the growing need for advanced medical technologies in emerging markets are further accelerating market expansion.Looking forward, United Imaging Healthcare plans to strengthen its global capabilities and enhance its brand presence. The company aims to accelerate its international expansion by leveraging its innovative product portfolio, comprehensive service networks, and efficient supply chains. This strategy positions United Imaging as a leader in both technology and market presence. The company is committed to fostering long-term, mutually beneficial partnerships with medical institutions around the world.

Answer：As AI in medical imaging is rapidly developing worldwide, pioneering technologies such as artificial intelligence deep learning and full digitization/metaverse integration are being combined with medical imaging diagnostic equipment. This integration accelerates image processing speed and improves the accuracy of information processing. In the MRI field, AI applications focus mainly on imaging acceleration, lesion detection, and workflow optimization. Our MRI equipment, featuring the uAIFI technology platform, leads the industry in fast imaging technology, enabling dynamic high-definition imaging at a speed of 0.5 seconds per phase. In the CT field, AI technology achieves low-dose scanning, image analysis, and fast image reconstruction, enhancing image quality and improving examination efficiency. In the Molecular Imaging (MI) field, AI applications are concentrated on radiotracer analysis and image registration. In the future, it will further advance the discovery of molecular markers and the monitoring of treatment responses. In the X-ray field, AI technology provides image enhancement, auxiliary diagnosis, and lesion detection, which facilitates immediate image interpretation and large-scale screening. In Radiotherapy (RT), AI applications assist in target delineation and automatic image segmentation, improving the homogeneity and accessibility of treatment. This helps address issues like uneven radiotherapy quality and the shortage of skilled professionals. These developments collectively support personalized medicine, real-time automated diagnosis, and provide more intelligent assistance and decision-making support for doctors. These technological advancements will further elevate overall healthcare standards and contribute to building a healthier world.

Answer：United Imaging Group ("the Group") encompasses several key subsidiaries, each contributing to different sectors of healthcare and technology, working in synergy to create an innovative and comprehensive healthcare ecosystem. The subsidiaries and their respective roles are as follows: United Imaging Healthcare (Founded in March 2011, headquartered in Shanghai) is the core subsidiary of the Group, primarily focused on providing a wide range of high-end medical imaging diagnostic products, radiotherapy equipment, life sciences instruments, and healthcare IT solutions. With a global presence, including regional headquarters and R&D centers in the U.S., Malaysia, UAE, and Poland, United Imaging Healthcare has established itself as an industry leader through its extensive R&D, production, and service networks.
United Imaging Intelligence (Established in December 2017) focuses on the development, production, and sales of AI-driven decision support products. Based in Shanghai with additional R&D centers in Beijing, Wuhan, Chengdu, and the U.S., United Imaging Intelligence plays a crucial role in advancing the Group's artificial intelligence initiatives. It provides AI-powered solutions and technical services, making it a key player in the medical imaging AI space.
United Imaging Wisdom (Founded in October 2016) specializes in the investment, management, and operation of precision medical imaging diagnostic services. By leveraging internet hospitals and third-party diagnostic centers across China, it breaks regional barriers, offering a dual-drive model combining online and offline professional medical imaging services to enhance access to high-quality medical resources.
United Imaging Integration(Established in February 2019) focuses on the development, production, and sales of surgical robots, 3D printing consumables, wearable medical devices, rehabilitation equipment, and chronic disease management systems. With subsidiaries and R&D centers in Shanghai, Shenzhen, and Changzhou, United Imaging Integration complements the Group's portfolio by expanding into medical technologies beyond radiotherapy, including robotic surgery and chronic disease management. United Imaging Microelectronics (Founded in June 2019) specializes in the R&D of custom high-end medical chips, AI medical chips, and wearable medical chips. The subsidiary provides system solutions based on these chips, with a vision to lead the health-tech chip sector globally. United Imaging Microelectronics aims to revolutionize the performance and cost-efficiency of advanced medical equipment, contributing to the accessibility of high-quality healthcare services.
These subsidiaries collaborate and leverage their specialized R&D capabilities to deliver comprehensive, innovative solutions that cover the entire healthcare process, from prevention and diagnosis to treatment and rehabilitation. United Imaging Healthcare remains the central pillar of the Group, while the other subsidiaries expand and enhance the Group's capabilities in areas such as artificial intelligence, precision diagnostics, medical robotics, and advanced microelectronics. Together, they are building an integrated and intelligent healthcare ecosystem aimed at improving global health outcomes.

Answer：United Imaging Healthcare (UIH) is a publicly listed company on the Shanghai Stock Exchange STAR Market, with a private ownership structure that ensures strong leadership and governance stability.
As of April 30, 2025, the largest and controlling shareholder is United Imaging Healthcare Technology Group Co., Ltd., holding 20.33% of the company's voting rights. Together with affiliated investment entities controlled by Mr. Xue Min and the company's five Employee Stock Ownership Plan (ESOP) platforms, the ultimate controlling parties collectively hold over 30% of voting rights. This controlling stake has been consistently maintained over the past five years, firmly establishing United Imaging Group as the controlling shareholder.
Mr. Xue Min is the ultimate controller, effectively exercising 28.01% of UIH's voting rights through United Imaging Group, Shanghai Yingsheng Investment Partnership, and Shanghai Yingzhi Investment Partnership. This proportion has remained stable over the past five years and is significantly higher than that of any other individual shareholder. The remaining equity is widely dispersed, further reinforcing Mr. Xue Min's control.
As a listed company, UIH upholds the highest standards of transparency, disclosure, and regulatory compliance, ensuring investors have clear insight into its operations and governance. This commitment fosters global investor confidence and reflects strong market trust in UIH's governance and growth prospects.
Combining private ownership, visionary leadership, and public capital, UIH is well positioned to drive continuous innovation while maintaining robust corporate governance. The shareholder structure safeguards the company's strategic direction and supports its mission to become a global leader in medical imaging and healthcare. UIH remains dedicated to delivering sustainable growth and maximizing long-term value for all shareholders and stakeholders worldwide.